This study is in progress, not accepting new patients
Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)
Summary
- Eligibility
- for people ages 12 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedcompletion around
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Institut de Recherches Internationales Servier
- ID
- NCT04164901
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- About 331 people participating
- Last Updated